We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Think zebras, not horses

16 February 2011 By Robert Cyran

The contingent value rights structured for Sanofi’s purchase of Genzyme helped seal the $20 bln deal. It shows how financial engineering can sometimes bridge divides. But the complexity of CVRs and their unpopularity among investors should limit their use to very special cases.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)